(Q39420486)

11 September 2017

title

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. (English)

1 reference

11 September 2017

1 reference

Labrie F

1

1 reference

11 September 2017

Candas B

2

1 reference

11 September 2017

Cusan L

3

1 reference

11 September 2017

Gomez JL

4

1 reference

11 September 2017

Diamond P

5

1 reference

11 September 2017

Suburu R

6

1 reference

11 September 2017

Lemay M

7

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 February 1996

1 reference

11 September 2017

1 reference

11 September 2017

volume

47

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

212-217

1 reference

11 September 2017

cites work

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Endocrine therapy of prostate cancer: optimal form and timing

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Use of transrectal ultrasound in diagnosis, guided biopsy, staging, and screening of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Influence of benign prostatic hyperplasia, testosterone and age on serum levels of prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

The national survey of prostate cancer in the United States by the American College of Surgeons

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Cancer screening. Degrees of proof and practical application

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

The impact of family history on early detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Management of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Heterogeneity of prostate cancer in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

High 10-year survival rate in patients with early, untreated prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Deferred treatment in clinically localised prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980419-1

7 January 2021

10.1016/S0090-4295(99)80419-1

Identifiers

DOI

1 reference

11 September 2017

1 reference